Is NCT07049328 recruiting in Tampa, FL?

Yes, NCT07049328 is currently recruiting participants at its Tampa, FL location. This alopecia areata(aa) clinical trial is actively enrolling qualified participants.

How do I join the alopecia areata(aa) clinical trial in Tampa?

To join this clinical trial in Tampa, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Tampa clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Alopecia Areata(AA) Clinical Trial in Tampa, FL

Who Can Participate

Inclusion Criteria

Adult women who are 18 to 70 years of age, or adult males who are 18 to 60 years of age at the time of informed consent.

Clinical diagnosis of Alopecia Areata (AA) (including ophiasis, totalis or universalis forms) at Screening.

Negative serum pregnancy test within 14 days of treatment start if female and of childbearing potential (non-childbearing is defined as greater than one year postmenopausal or surgically sterilized).

Female subjects of childbearing potential must adhere to using a highly effective medically accepted method of birth control (defined as those with failure less than 1%; see Appendix 2) prior to screening and agree to continue its use for at least 28 days after the last dose of HCW9302 or be surgically sterilized (e.g., hysterectomy or tubal ligation) and males must agree to use a barrier method of birth control and agree to continue its use for at least 28 days after the last dose of HCW9302.

Laboratory tests performed within 28 days of treatment start:

Absolute neutrophil count (AGC/ANC) ≥ 1,500/μL (≥1.5 × 109/L)

Platelets ≥ 100,000/μL (≥ 100 × 109/L)

Hemoglobin ≥ 10 g/dL (\>100g/L)

Calculated glomerular filtration rate (GFR)\

\>40 mL/min OR serum creatinine ≤ 1.5 × ULN

Total bilirubin ≤ 2.0 × ULN or ≤ 3.0 × ULN for subjects with Gilbert's syndrome

AST, ALT, ALP ≤ 2.0 × ULN

Able and willing to comply with requested study visits and procedures.

Able and willing to provide written informed consent and HIPAA authorization

Exclusion Criteria

Men and women (of reproductive potential) unwilling to use birth control and women who are pregnant or breastfeeding

Patient has primarily "diffuse" type AA (characterized by diffuse hair shedding)

Presence of another form of alopecia

Prior use of any of the following treatments: a. Aldesleukin b. Investigational IL-2 analog

Concurrent use of oral or topical treatments targeting hair growth or hair restoration (including but not limited to finasteride, dutasteride, topical minoxidil or oral minoxidil) if discontinuation or dosage change is planned during the study period.

Prior use of phototherapy and any systemic immunosuppressant (systemic steroids, cyclosporin, methotrexate or any other immunosuppressive therapy) or immunomodulating biologic therapy (including but not limited to dupilumab, tralokinumab, lebrikizumab, nemolizumab, rocatinlimab, or daxdilimab, whether marketed or investigational) within 3 months prior to Screening.

Prior use of any B-cell depleting agents, whether marketed or investigational, including but not limited to rituximab, ocrelizumab, ofatumumab, or belimumab, within 6 months prior to Screening.

Known hypersensitivity or history of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in the study.

History of diabetes mellitus, regardless of whether it is controlled or not.

History of myocardial infarction, congestive heart failure, uncontrolled arrhythmias, cardiac revascularization, stroke, uncontrolled hypertension, or uncontrolled diabetes within 6 months prior to Screening.

Significant organ dysfunction that is unstable or inadequately treated within 6 months prior to Screening.

History of cancer or lymphoproliferative disease, except for the following: adequately treated basal cell or squamous cell skin cancer without current evidence of disease.

Currently receiving any chronic systemic (oral or intravenous) anti-infective therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical mycobacteria).

Active tuberculosis (TB) (based on TB blood test or a TB skin test) or a history of inadequately treated TB.

Herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months prior to Screening. Subjects with a history of frequent outbreaks of Herpes Simplex Virus (defined as 4 or more outbreaks a year).

Major surgery within 3 months prior to Screening visit or has a major surgery planned during the study.

Active systemic infection requiring parenteral antibiotic/antiviral therapy. All prior infections must have resolved following optimal therapy.

Prior organ allograft or allogeneic transplantation.

Positive based on serological screening for human immunodeficiency virus (HIV), hepatitis B or hepatitis C at screening.

Any ongoing toxicity from prior therapies that, in the judgment of the Investigator, may interfere with study treatment. All toxicities attributed to prior therapy must resolve to grade 1 or baseline before administration of the study treatment.

Psychiatric illness/social situations that would limit compliance with study requirements.

Other skin conditions that would interfere with study assessments of AA.

Other illness or a medical issue that in the opinion of the Investigator would exclude the subject from participating in this study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tampa?

Yes, this clinical trial (NCT07049328) has an active research site in Tampa, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Alopecia Areata(AA) Treatment Options in Tampa, FL

If you're searching for alopecia areata(aa) treatment options in Tampa, FL, this clinical trial (NCT07049328) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tampa research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced alopecia areata(aa) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all alopecia areata(aa) clinical trials near you to find additional studies recruiting in your area.

Alopecia Areata(AA) Clinical Trial in Tampa, FL

Expert Care in Tampa

IRB Approved

No-Cost Care

Apply for This Tampa Location

Why Participate?

Simple Process

About This Alopecia Areata(AA) Study in Tampa